ArticleBMC medicine2019
Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma.
Article in BMC medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- GCNT3 Promotes Hepatocellular Carcinoma Progression and EMT by Activating the PI3K/AKT Pathway.Biochemical genetics · 2025Article
- Targeting HMGB2 acts as dual immunomodulator by bolstering CD8Science advances · 2025Article
- Machine learning-based identification of core regulatory genes in hepatocellular carcinoma: insights from lactylation modification and liver regeneration-related genes.Frontiers in oncology · 2025Article
- A novel prognostic model to predict prognosis of patients with osteosarcoma based on clinical characteristics and blood biomarkers.Journal of Cancer · 2025Article
- Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- DeepRisk network: an AI-based tool for digital pathology signature and treatment responsiveness of gastric cancer using whole-slide images.Journal of translational medicine · 2024Article
- Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.Frontiers in immunology · 2024Review
- The value of CDC42 effector protein 2 as a novel prognostic biomarker in liver hepatocellular carcinoma: a comprehensive data analysis.Osong public health and research perspectives · 2023Article
- Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.Hepatology international · 2023Article
- A novel quantitative prognostic model for initially diagnosed non-small cell lung cancer with brain metastases.Cancer cell international · 2022Article
- Preoperative Prognostic Nutritional Index May Be a Strong Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.Journal of hepatocellular carcinoma · 2022Article
- Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning.Frontiers in oncology · 2022Article
- Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma.Cancer cell international · 2021Article
- LPCAT1 overexpression promotes the progression of hepatocellular carcinoma.Cancer cell international · 2021Article
- Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC.Scientific reports · 2021Article
- Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma.Cancers · 2021Article
- Systematic Characterization of Novel Immune Gene Signatures Predicts Prognostic Factors in Hepatocellular Carcinoma.Frontiers in cell and developmental biology · 2021Article
- Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma.Molecular imaging · 2021Article
- RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma.Frontiers in oncology · 2021Article
- Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundIntratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC.
methodsTwenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model.
resultsBy using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3
conclusionsOur ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.